PDCD1 and cancer: Antibodies against cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed cell death protein 1 (PD-1) and its ligands (PD-L1/PD-L2) can modulate the immune response to cancer clearance in a various human malignancies.